Foghorn Therapeutics (FHTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on the stock and has a $13.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight Foghorn Therapeutics’ innovative approach and promising clinical developments. The company’s lead candidate, FHD-909, is a first-in-class oral selective SMARCA2 inhibitor that has shown significant potential in preclinical studies, particularly for treating non-small cell lung cancer (NSCLC) with SMARCA4 mutations. The data presented at the AACR 2025 conference demonstrated robust tumor regression in various NSCLC models, underscoring the drug’s targeted efficacy.
Additionally, Foghorn’s strategic exploration of combination therapies with FHD-909, including its synergy with standard treatments like platinum-based chemotherapies and checkpoint inhibitors, further strengthens its clinical prospects. Beyond FHD-909, Foghorn’s pipeline includes promising programs like the CBP degrader and selective EP300 degrader, which have shown potential in preclinical models for various cancers. These advancements, coupled with the company’s innovative approach to targeting synthetic lethal relationships in oncology, provide a strong basis for the Buy rating.
In another report released today, JMP Securities also maintained a Buy rating on the stock with a $9.00 price target.